4 completed, 2 terminated, 2 unknown, 1 active not recruiting. 3 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 2 | Terminated 1, Unknown 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Oncogenic osteomalacia: new trials by email Literature Review of Oncogenic osteomalacia trials Research Report on Oncogenic osteomalacia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Al18F-NOTA-LM3 PET/CT in Patients With TIO Diagnostic Test: Al18F-NOTA-LM3, Diagnostic Test: 68Ga-DOTATATE - Tumor-Induced Osteomalacia | Not applicable | Recruiting | Peking Union Medical College Hospital | 40 | 2023-03-30 | 2026-01-26 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO KRN23 - Tumor-Induced Osteomalacia (TIO) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 9 | 2022-09-07 | 2024-07-09 |
| Tumor-induced Osteomalacia Disease Monitoring Program No intervention - Tumor-induced Osteomalacia (TIO) | Active not recruiting | Ultragenyx Pharmaceutical Inc | 23 | 2022-01-31 | 2026-11-04 | |
| Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO 68Ga-Dotatate, 68Ga-DOTA-JR11 - Tumor-Induced Osteomalacia | Phase 1 | Unknown | Peking Union Medical College Hospital | 50 | 2020-03-15 | 2021-01-05 |
| BGJ398 for the Treatment of Tumor-Induced Osteomalacia BGJ398 - Tumor-Induced Osteomalacia, Oncogenic Osteomalacia | Phase 2 | Terminated | National Institute of Dental and Craniofacial Research (NIDCR) | 4 | 2019-02-27 | 2026-11-10 |
| A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome KRN23 - Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 14 | 2016-04-01 | 2022-09-06 |
| Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) Burosumab - Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS) | Phase 2 | Completed | Kyowa Kirin, Inc. | 17 | 2015-03-24 | 2024-05-06 |
| Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) Osteomalacia - Osteomalacia | Phase 1 | Terminated | National Institute of Dental and Craniofacial Research (NIDCR) | 1 | 2012-11-16 | 2018-07-05 |
| 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia 68Ga-DOTATATE - Oncogenic Osteomalacia, Mesenchymal Tumor | Early Phase 1 | Unknown | Peking Union Medical College Hospital | 100 | 2011-12-01 | 2017-04-07 |
| Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia Osteomalacia, Neoplasms | Completed | National Institute of Dental and Craniofacial Research (NIDCR) | 45 | 2004-12-15 | 2017-07-02 | |
| Expanded Access to Burosumab Burosumab - X-linked Hypophosphatemia, Tumor-Induced Osteomalacia | Available | Kyowa Kirin Co., Ltd. | 2025-03-05 |
Hypophosphatemia (2) · Nevus, Sebaceous of Jadassohn (2) · Osteomalacia (2) · Familial Hypophosphatemic Rickets (1) · Neoplasms (1) · Rickets, Hypophosphatemic (1)
Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Phosphorus Metabolism Disorders (4) · Avitaminosis (3) · Bone Diseases (3) · Bone Diseases, Metabolic (3) · Calcium Metabolism Disorders (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Deficiency Diseases (3) · Malnutrition (3) · Musculoskeletal Diseases (3) · Nutrition Disorders (3) · Rickets (3) · Vitamin D Deficiency (3) · Abnormalities, Multiple (2)
burosumab (4) · gallium Ga 68 dotatate (2) · infigratinib (1)
Kyowa Kirin Co., Ltd. (3) · National Institute of Dental and Craniofacial Research (NIDCR) (3) · Peking Union Medical College Hospital (3) · Kyowa Kirin, Inc. (1) · Ultragenyx Pharmaceutical Inc (1)
United States (5) · China (4) · Argentina (1) · Japan (1) · South Korea (1)
Rachel I Gafni, M.D. (2) · Fang Li, MD (1) · Hongli Jing, MD (1)